Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11676
Title: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.
Austin Authors: Tebbutt, Niall C ;Parry, M M;Zannino, D;Strickland, A H;Van Hazel, G A;Pavlakis, N;Ganju, V;Mellor, D;Dobrovic, Alexander ;Gebski, V J
Institutional Author: Australasian Gastro-Intestinal Trials Group (AGITG)
Affiliation: niall.tebbutt@ludwig.edu.au
Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
Issue Date: 14-Feb-2013
Publication information: British Journal of Cancer 2013; 108(4): 771-4
Abstract: Cetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric cancer.Patients received docetaxel 30 mg m(-2) on days 1 and 8, every 3 weeks and cetuximab 400 mg m(-2) on day 1, then 250 mg m(-2) weekly. Biomarker mutation analysis was performed.A total of 38 patients were enrolled. Response rates were PR 6% (95% CI 2-19%), s.d. 43% (95% CI 28-59%). Main grade 3/4 toxicities were febrile neutropenia, anorexia, nausea, diarrhoea, stomatitis, and acneiform rash. Median progression-free and overall survival were 2.1 and 5.4 months, respectively. A landmark analysis showed a trend to improved survival times with increased grade of acneiform rash. No KRAS, BRAF or PIK3CA mutations were observed.Cetuximab and docetaxel achieve modest responses rates, but maintain comparable survival times to other salvage regimens with low rates of toxicity.
Gov't Doc #: 23412099
URI: http://ahro.austin.org.au/austinjspui/handle/1/11676
DOI: 10.1038/bjc.2013.41
URL: https://pubmed.ncbi.nlm.nih.gov/23412099
Type: Journal Article
Subjects: Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal.administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic use
Drug Administration Schedule
Drug Resistance, Neoplasm
Esophageal Neoplasms.drug therapy.mortality
Esophagogastric Junction
Humans
Middle Aged
Quality of Life
Stomach Neoplasms.drug therapy.mortality
Taxoids.administration & dosage
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Nov 25, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.